Lupus & antiphospholipid syndrome
Alignment of contraception use with the American College of Rheumatology (ACR) reproductive health guidelines in women with systemic lupus erythematosus within the Rheumatology Informatics System for Effectiveness (RISE) registry
Authors' conclusion
Practices participating in the RISE registry do not currently record contraception in the large majority of women with SLE, although increased documentation in some EHRs suggests that system changes may improve rates of documentation.
Study context
- Population
- Female patients (aged 18–44 years) with SLE in the RISE registry, rheumatology clinics across the USA
- Exposure
- Prepandemic vs mid-pandemic; contraception patterns compared with the 2020 ACR guidelines
- Outcome
- Contraception documentation and its predictors; alignment of contraception practices with the 2020 ACR guidelines
Methodological detailsregistry-based, multicentre, adjusted multilevel logistic modelling
- Registry-based
- Multicentre
- Adjusted multilevel logistic modelling
Main finding
As reported in the abstract
Contraception documentation rate
Observational data: associations, not effects.
Further findings
With thrombotic risk vs Without thrombotic risk
Oestrogen-containing contraceptive prescription by thrombotic risk
P < 0.0001
With history of lupus nephritis (LN) vs Without history of LN
Oestrogen-containing contraceptive prescription by history of LN
P = 0.024
Original publication
Alignment of contraception use with the ACR reproductive health guidelines in women with systemic lupus erythematosus within the RISE registry. Lupus Sci Med. Published 24 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →